Antalnox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antalnox

Quick Facts

Property Description
Active ingredient Naproxen Sodium (salt form of Naproxen)
Form Oral Solid (e.g., film-coated tablet)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic (Propionic acid derivative)

Antalnox: Identity and Pharmacological Classification

Antalnox is a chemically synthesized, single-agent pharmaceutical entity belonging to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. This means it is widely recognized for its efficacy in managing discomfort linked to the body's inflammatory response. The active substance is a propionic acid derivative, placing it within a family of common analgesics. A distinctive feature of its active moiety, naproxen, is its relatively long half-life compared to many other nonsteroidal compounds. This sustained pharmacological presence supports a less frequent dosing schedule, which provides a convenience factor for continuous symptomatic control throughout the day.

Active Ingredient and Drug Form (Naproxen Sodium)

The functional component of Antalnox is the salt form, Naproxen Sodium. The formulation utilizes the sodium salt to enhance the drug's solubility, a design feature engineered to achieve a rapid onset of action after ingestion. This accelerated dissolution rate is a fundamental differentiation point, making the medication suitable for situations requiring prompt relief. Antalnox is distributed primarily as an oral solid dosage form, typically a film-coated tablet, ensuring predictable delivery of the active substance into the systemic circulation.

General Purpose and Symptomatic Relief

The overarching purpose of Antalnox is to deliver effective symptomatic relief by mitigating the physiological effects associated with inflammatory processes. Its action is achieved through the non-selective inhibition of cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins, the primary chemical signals for pain and swelling. The resultant benefit is a comprehensive triad of effects—relief from discomfort (analgesia), reduction of elevated body temperature (antipyresis), and a decrease in localized swelling (anti-inflammation).

Regulatory References

  1. National Institutes of Health (NIH)
  2. MedlinePlus

What side effects are possible with Antalnox?

Possible Side Effects and Safety Information

Antalnox, which contains Naproxen Sodium and belongs to the NSAID class, has a safety profile defined by official government regulatory documents (such as the FDA Prescribing Information and EMA Summary of Product Characteristics). The adverse reactions are systematically classified by the body systems they affect, with the Gastrointestinal and Cardiovascular Systems representing the primary domains of official safety concern.


Adverse Reaction Classification

Side effects are classified by their frequency based on aggregated regulatory data:

Classification Examples of Documented Adverse Reactions
Common Dyspepsia (indigestion), abdominal pain, nausea, headache, dizziness, drowsiness, skin rash, fluid retention (edema).
Less Common/Rare Gastrointestinal bleeding, ulceration, severe hepatic (liver) reactions, severe dermatologic reactions, and anaphylaxis.

Serious Adverse Reactions and Safety Patterns

The label explicitly documents the potential for Serious Adverse Reactions (SARs). These include Serious Cardiovascular Thrombotic Events (such as myocardial infarction and stroke) and Serious Gastrointestinal Adverse Events (including bleeding and perforation), which can occur without warning. Regulatory documents note that the cardiovascular risk may occur early and increase with the duration of use.

Population-Specific Safety Notes

The safety profile includes constraints for specific populations. Older adults are noted to have a greater risk for serious gastrointestinal and renal adverse events. The medicine is contraindicated in the third trimester of pregnancy due to the potential risk of premature closure of the fetal ductus arteriosus, and is also contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Overdose and Emergency Response

The official regulatory profile for Antalnox (Naproxen Sodium) overdose details specific clinical manifestations and mandated emergency responses, based strictly on government-authorized labeling.

Manifestations & Risks Regulatory Statements
Documented Presentation Symptoms of overexposure include typical gastrointestinal distress (nausea, vomiting, epigastric pain), along with neurological findings such as dizziness, drowsiness, lethargy, and ringing in the ears (tinnitus). Metabolic acidosis is a documented physiological finding.
Severe Outcomes Regulatory documents specify the risk of life-threatening outcomes, including acute renal failure, seizures or coma, and severe gastrointestinal bleeding.
Population Note The official labeling notes that elderly patients and individuals with pre-existing renal impairment carry an increased susceptibility to severe adverse events from overexposure.

Emergency Action & Management Regulatory Statements
Immediate Action Required Regulators explicitly instruct individuals to seek immediate medical attention and contact a Poison Control Center following any suspected or substantial overdose ingestion.
Management Focus Treatment is strictly symptomatic and supportive, as the label states no specific antidote is known.
Procedural Measures Supportive management may include the administration of activated charcoal or gastric lavage, particularly if performed within one hour of ingestion. Hospital monitoring of renal function and vital signs is required.

Therapeutic Uses of Antalnox

What Antalnox Treats: Main Uses and Benefits

Antalnox is indicated for the symptomatic management of a variety of painful and inflammatory conditions. Its primary use includes addressing chronic inflammatory rheumatisms, such as rheumatoid arthritis and ankylosing spondylitis, and certain painful arthroses. It is also commonly prescribed for the short-term relief of acute episodes, including tendinitis, bursitis, acute low back pain (lombalgies), radiculalgia, and soft-tissue injuries following trauma. By providing a reduction in pain and inflammation, the medicine supports the patient’s ability to return to daily activity.

Clinical use is generally directed at employing the lowest dose possible for the shortest duration necessary to relieve symptoms.


Quick Fact: Relief for Joint and Muscle Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Antalnox?

The eligibility for Antalnox (Naproxen Sodium) is strictly defined by regulatory documents, distinguishing between approved populations, conditional use, and absolute prohibitions (contraindications). These rules govern safe use based on patient status and preexisting conditions.

Population Status Rules for Use (Official Regulatory Status)
Contraindicated Use is absolutely prohibited in patients with a known hypersensitivity to naproxen or any NSAID, in the peri-operative setting of CABG surgery, and during the third trimester of pregnancy (starting at 30 weeks gestation).
Age-Group Eligibility Approved for use in adults and for OTC use in children 12 years and older. Safety and efficacy are not established for children under 2 years of age. Caution is specifically advised for older adults due to increased risks.
Restricted Use The medicine is not recommended or avoided in patients with advanced renal disease, severe heart failure, and active gastrointestinal bleeding or ulceration. Individuals with a history of these conditions require special consideration and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Antalnox (Naproxen Sodium) has officially documented interaction patterns that are classified primarily as pharmacodynamic reinforcement and pharmacokinetic exposure modification. These interactions, based on regulatory labeling, establish strict co-administration cautions and restrictions.

Formal Regulatory Restrictions

Co-administration is contraindicated for the management of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Concomitant use with other analgesic doses of NSAIDs is not recommended due to an increased risk of serious gastrointestinal events.

Clinically Significant Interactions

Interacting Substance Category Official Interaction Outcome (as per Label)
Anticoagulants and Antiplatelet Agents Increased risk of serious bleeding events due to additive effects.
Anti-hypertensives (ACE inhibitors, ARBs, Diuretics) May diminish the therapeutic effect of these blood pressure or volume-reducing medicines.
Lithium, Methotrexate, Digoxin Can increase the serum concentration and prolong the half-life of these medicines, raising the risk of toxicity.
Alcohol Ingestion increases the risk of gastric irritation and GI mucosal bleeding.

Population-Specific Cautions

Official documents note that the interaction with ACE inhibitors or ARBs may result in deterioration of renal function in specific populations, such as the elderly, volume-depleted, or those with existing renal impairment.

Mechanism of Action

Antalnox (Naproxen Sodium) exerts its physiological effects by operating within three core mechanistic domains, acting via inhibition of specific signaling enzymes at the molecular and systemic levels. The drug's action is entirely defined by how it modulates these specific enzyme systems and pathways.


Key Molecular Targets and Prostanoid Suppression

The foundational mechanism involves the reversible, non-selective inhibition of the Cyclooxygenase (COX) enzyme system, primarily targeting both the constitutive COX-1 and the inducible COX-2 isoforms. By blocking the active site of these enzymes, the molecule curtails the production of lipid-derived signaling molecules, such as prostaglandins, which are central drivers of specific physiological responses.


Modulation of Nociceptive and Thermal Pathways

The resultant suppression of prostaglandins leads to dual physiological consequences. Peripherally, it reduces the chemical sensitization of nociceptors (pain fibers), leading to elevated nociceptor desensitization thresholds. Centrally, it reduces the synthesis of Prostaglandin E2 (PGE2) within the hypothalamus, which modulates the elevated hypothalamic thermal set point.


Mechanism of Accelerated Engagement

The drug's formulation as a sodium salt is a design feature that enhances its dissolution rate, which directly impacts the speed of its mechanistic engagement. This accelerated solubility allows the active molecule to reach the COX enzyme targets rapidly, allowing for rapid attainment of effective target engagement.

Dosage and Administration Information

Official Instructions for Use

Administration of Antalnox must strictly follow the dosing and duration rules established by the prescriber. Standard clinical practice involves using the lowest effective dose for the shortest duration of treatment necessary to achieve relief.

Dosing and Timing

Guideline Instruction
Route Oral (swallowed tablet).
Total Daily Dose The maximum daily dose is 1100 mg.
Frequency The prescribed dosage is to be divided into 1 or 2 doses per day.
Timing with Meals The tablets should be taken with a large glass of water, preferably at mealtime.
Tablet Preparation The 550 mg tablet is scored and divisible for administration of half doses (275 mg), if prescribed.

Procedural Rules

Missed Dose: If a dose is forgotten, the instruction is to take it as soon as the patient remembers. However, if it is nearly time for the next scheduled dose, the forgotten dose should be skipped, and the patient should continue with the regular schedule. A double dose must never be taken to compensate for a missed one.

Duration: The total duration of use must adhere precisely to the period prescribed by the doctor. Treatment should be reviewed at regular intervals, and use should be discontinued if no benefit is observed. The final procedural structure is determined by the requirement for strict adherence to the dose and duration prescribed by the healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Antalnox

The following information summarizes the types of research and the patterns of findings reported in clinical studies on Antalnox. This is a descriptive overview of the evidence landscape and should not be used for making personal health decisions.

Evidence for Use in Chronic Inflammatory Conditions

Antalnox was studied in research exploring the outcomes related to physical discomfort and functional imbalance that characterize conditions like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Research includes short-term Randomized Controlled Trials (RCTs) and longer-term observational studies in adult populations. The studies monitored how symptoms evolved over defined time intervals, using tools like the WOMAC Index to measure patient-reported outcomes describing perceived discomfort. Findings described patterns observed in the studies related to pain and function when compared to a group receiving an inactive substance or when evaluated against other medications in the same class.

Evidence for Use in Acute Pain and Gout

The research base for acute pain, such as post-surgical pain, menstrual pain (dysmenorrhea), and acute gouty arthritis, is largely composed of double-blind, single-dose, or short-term multiple-dose RCTs. These trials examined temporary physiological imbalance and outcomes describing episodic or acute changes. For acute pain, studies reported measurements of pain intensity and total pain relief scores. Data show patterns related to measured changes in symptom levels and time to measured change in the acute episode when compared to a placebo or other active treatments.

What Is Still Uncertain About Antalnox Research

While the evidence landscape is established in many areas, research is still ongoing. Long-term effects are not fully established with the certainty of short-term trials, and the follow-up durations were limited relative to the lifelong nature of chronic conditions. Comparative evidence is lacking in large-scale, head-to-head trials against every available modern treatment option for certain conditions. Furthermore, data for many special populations, such as those with specific comorbidities, remain insufficient. Research provides context but not individual predictions.

Key Studies & References NAPROXEN (oral) - Official FDA Label / Drug Monograph

Frequently Asked Questions (FAQ)

Common questions about Antalnox (FAQ)


Q: How long do the effects of Antalnox typically last?

According to official product information, the active substance in Antalnox has an elimination half-life that typically ranges from 12 to 17 hours.

This half-life is a measure of how long it takes for half of the drug to be eliminated from the body, and this prolonged duration is a factor considered in establishing the typical dosing schedule.


Q: Can Antalnox be taken with common over-the-counter medicines?

Official regulatory labels state that Antalnox should not be taken with other non-steroidal anti-inflammatory drugs (NSAIDs) due to the increased risk of adverse events.

However, regulatory information in some countries indicates that it may be taken concurrently with paracetamol (acetaminophen) for short periods. Co-administration with other medicines is a topic best discussed with a healthcare professional.


Q: Are there any specific foods or drinks to avoid while taking Antalnox?

Regulatory documents indicate that taking Antalnox tablets with food may prolong the time it takes for the drug to reach its maximum concentration in the bloodstream.

Beyond the stated caution regarding alcohol, official labeling does not specify prohibitions for particular types of food.


Q: Is Antalnox available over the counter in some countries?

Official labeling shows that Antalnox is available in both prescription strength and in lower-dose, over-the-counter (OTC) formulations.

The availability depends entirely on the specific dosage and the regulations of the country or region.


Q: What should I know about the 'black box warning' mentioned for Antalnox?

Regulatory documents include a prominent safety warning, sometimes referred to as a Boxed Warning, to highlight potential serious risks.

This warning concerns the potential for serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal adverse events, which include bleeding, ulceration, and perforation. Official information states these risks may occur early and increase with duration of use.


Q: Does Antalnox interact with herbal supplements like St. John's Wort?

Official cautions note that complementary and herbal medicines are generally not studied for drug interactions in the same rigorous manner as prescription drugs.

For this reason, official information indicates that co-administration of Antalnox with any herbal or natural health product is a topic for discussion with a health provider.


Q: Why is Antalnox only available by prescription?

The necessity of a prescription for certain dosage strengths is based on the potential for serious adverse reactions, as defined in regulatory documents.

Official guidance indicates that clinical supervision and periodic monitoring of patient progress are required when prescribing these higher doses.


Q: Is Antalnox chemically related to ibuprofen or acetaminophen?

Official regulatory classification places Antalnox in the Nonsteroidal Anti-inflammatory Drug (NSAID) class, which is the same class as ibuprofen.

However, Antalnox is not chemically related to acetaminophen (often known as paracetamol), which belongs to a different drug class.


Q: What is the risk of dependence or addiction with Antalnox?

Regulatory documents classify Antalnox (Naproxen Sodium) as a substance that is not scheduled by the Drug Enforcement Administration (DEA).

This means it is not associated with the risks of dependence or addiction typically seen with narcotic or controlled substances.


Q: Is there a generic version of Antalnox available?

Official regulatory labeling includes references to Abbreviated New Drug Applications (ANDA) and other generic labels.

This regulatory pathway confirms that generic versions of the drug exist and are available.


Q: Can Antalnox be used while breastfeeding?

Information summarized in the NIH's LactMed database suggests that the levels of the active substance that pass into breast milk are generally low.

However, due to the drug’s relatively long half-life, official documents suggest that caution may be necessary when the medicine is used while breastfeeding, especially for newborns or preterm infants.


Q: What are the signs of an allergic reaction to Antalnox?

Official labels contain warnings that symptoms of a severe allergic reaction may include the onset of hives, swelling of the face, or wheezing and trouble breathing.

More severe reactions may present as skin reddening, rash, and blistering.


Q: Do regulatory agencies classify Antalnox as a controlled substance?

Regulatory records consistently classify Antalnox (Naproxen Sodium) as a substance that is not scheduled by the Drug Enforcement Administration (DEA).

This means it is not subject to the same strict controls as certain other medications.


Q: Do I need to change my activities while taking Antalnox?

Due to the documented potential for common central nervous system side effects, such as drowsiness and dizziness, regulatory information implies that caution is necessary when considering activities that require mental alertness.

This consideration is based purely on the risk described in the safety profile.


Q: Is it possible to take Antalnox while operating machinery?

As the drug's safety profile has been associated with central nervous system side effects, including dizziness and drowsiness, regulatory warnings indicate that caution is necessary when considering driving or operating hazardous machinery.


Q: Does Antalnox affect blood sugar levels?

Official regulatory documents note that in rare or unclassified cases, the use of Antalnox has been associated with documented changes in blood sugar levels.

This includes reports of both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar).

How should Antalnox be stored and disposed of?

Official Storage and Disposal Requirements

The storage requirements for Antalnox (Naproxen Sodium) are strictly defined by regulatory documents to maintain its quality and stability.

Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature: 20 C to 25 C (68 F to 77 F), avoiding excessive heat above 40 C (104 F). Do not refrigerate or freeze.
Protection Keep the product in the original, tightly closed container. Protect from both light and high humidity.
Safety The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Antalnox must be done in accordance with local requirements. The recommended method is to use a community drug take-back program. If this is unavailable, the product should be mixed with an undesirable substance, sealed in a container, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antalnox found in:

A-Z Index: